Balugrastim Biosimilar Fusion Protein (G-CSF Receptor) for Research

Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Balugrastim has been used in trials studying the treatment of Solid Tumors. Neutropenia is one of the most common toxicities in cancer patients receiving myelosuppressive chemotherapy. Patients who develop neutropenia are at increased risk for infection with fever. Balugrastim is a recombinant granulocyte colony-stimulating factors (G-CSFs) reduce the incidence and duration of chemotherapy-induced neutropenia and febrile neutropenia when given as adjunct therapy to patients receiving myelosuppressive chemotherapy. Balugrastim is a long-acting G-CSF composed of a genetic fusion between recombinant human serum albumin and G-CSF.